#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0011] Regardless of which of the three key versions of the probe reagent is used, there are numerous variations that apply equally to each version of the invented reagent.
1-1	0-1	[	_	_	
1-2	1-5	0011	_	_	
1-3	5-6	]	_	_	
1-4	7-17	Regardless	_	_	
1-5	18-20	of	_	_	
1-6	21-26	which	_	_	
1-7	27-29	of	_	_	
1-8	30-33	the	_	_	
1-9	34-39	three	_	_	
1-10	40-43	key	_	_	
1-11	44-52	versions	_	_	
1-12	53-55	of	_	_	
1-13	56-59	the	_	_	
1-14	60-65	probe	_	_	
1-15	66-73	reagent	_	_	
1-16	74-76	is	_	_	
1-17	77-81	used	_	_	
1-18	81-82	,	_	_	
1-19	83-88	there	_	_	
1-20	89-92	are	_	_	
1-21	93-101	numerous	_	_	
1-22	102-112	variations	_	_	
1-23	113-117	that	_	_	
1-24	118-123	apply	_	_	
1-25	124-131	equally	_	_	
1-26	132-134	to	_	_	
1-27	135-139	each	_	_	
1-28	140-147	version	_	_	
1-29	148-150	of	_	_	
1-30	151-154	the	_	_	
1-31	155-163	invented	_	_	
1-32	164-171	reagent	_	_	
1-33	171-172	.	_	_	

#Text=For example, in accordance with one embodiment, the first probe and the second probe may be either soluble probes or immobilized probes.
2-1	173-176	For	_	_	
2-2	177-184	example	_	_	
2-3	184-185	,	_	_	
2-4	186-188	in	_	_	
2-5	189-199	accordance	_	_	
2-6	200-204	with	_	_	
2-7	205-208	one	_	_	
2-8	209-219	embodiment	_	_	
2-9	219-220	,	_	_	
2-10	221-224	the	_	_	
2-11	225-230	first	_	_	
2-12	231-236	probe	_	_	
2-13	237-240	and	_	_	
2-14	241-244	the	_	_	
2-15	245-251	second	_	_	
2-16	252-257	probe	_	_	
2-17	258-261	may	_	_	
2-18	262-264	be	_	_	
2-19	265-271	either	_	_	
2-20	272-279	soluble	_	_	
2-21	280-286	probes	_	_	
2-22	287-289	or	_	_	
2-23	290-301	immobilized	_	_	
2-24	302-308	probes	_	_	
2-25	308-309	.	_	_	

#Text=In either instance, the first oligonucleotide sequence may include the complement of the first analyte sequence, or alternatively may have exactly the complement of the first analyte sequence without additional sequence.
3-1	310-312	In	_	_	
3-2	313-319	either	_	_	
3-3	320-328	instance	_	_	
3-4	328-329	,	_	_	
3-5	330-333	the	_	_	
3-6	334-339	first	_	_	
3-7	340-355	oligonucleotide	_	_	
3-8	356-364	sequence	_	_	
3-9	365-368	may	_	_	
3-10	369-376	include	_	_	
3-11	377-380	the	_	_	
3-12	381-391	complement	_	_	
3-13	392-394	of	_	_	
3-14	395-398	the	_	_	
3-15	399-404	first	_	_	
3-16	405-412	analyte	_	_	
3-17	413-421	sequence	_	_	
3-18	421-422	,	_	_	
3-19	423-425	or	_	_	
3-20	426-439	alternatively	_	_	
3-21	440-443	may	_	_	
3-22	444-448	have	_	_	
3-23	449-456	exactly	_	_	
3-24	457-460	the	_	_	
3-25	461-471	complement	_	_	
3-26	472-474	of	_	_	
3-27	475-478	the	_	_	
3-28	479-484	first	_	_	
3-29	485-492	analyte	_	_	
3-30	493-501	sequence	_	_	
3-31	502-509	without	_	_	
3-32	510-520	additional	_	_	
3-33	521-529	sequence	_	_	
3-34	529-530	.	_	_	

#Text=In another instance, regardless of whether the two probes are soluble or immobilized, the first oligonucleotide sequence and the second oligonucleotide sequence may be identical to each other.
4-1	531-533	In	_	_	
4-2	534-541	another	_	_	
4-3	542-550	instance	_	_	
4-4	550-551	,	_	_	
4-5	552-562	regardless	_	_	
4-6	563-565	of	_	_	
4-7	566-573	whether	_	_	
4-8	574-577	the	_	_	
4-9	578-581	two	_	_	
4-10	582-588	probes	_	_	
4-11	589-592	are	_	_	
4-12	593-600	soluble	_	_	
4-13	601-603	or	_	_	
4-14	604-615	immobilized	_	_	
4-15	615-616	,	_	_	
4-16	617-620	the	_	_	
4-17	621-626	first	_	_	
4-18	627-642	oligonucleotide	_	_	
4-19	643-651	sequence	_	_	
4-20	652-655	and	_	_	
4-21	656-659	the	_	_	
4-22	660-666	second	_	_	
4-23	667-682	oligonucleotide	_	_	
4-24	683-691	sequence	_	_	
4-25	692-695	may	_	_	
4-26	696-698	be	_	_	
4-27	699-708	identical	_	_	
4-28	709-711	to	_	_	
4-29	712-716	each	_	_	
4-30	717-722	other	_	_	
4-31	722-723	.	_	_	

#Text=When this is the case, at least one of the two probes may include a nucleotide analog.
5-1	724-728	When	_	_	
5-2	729-733	this	_	_	
5-3	734-736	is	_	_	
5-4	737-740	the	_	_	
5-5	741-745	case	_	_	
5-6	745-746	,	_	_	
5-7	747-749	at	_	_	
5-8	750-755	least	_	_	
5-9	756-759	one	_	_	
5-10	760-762	of	_	_	
5-11	763-766	the	_	_	
5-12	767-770	two	_	_	
5-13	771-777	probes	_	_	
5-14	778-781	may	_	_	
5-15	782-789	include	_	_	
5-16	790-791	a	_	_	
5-17	792-802	nucleotide	_	_	
5-18	803-809	analog	_	_	
5-19	809-810	.	_	_	

#Text=Again regardless of whether the two probes are soluble or immobilized, the first oligonucleotide sequence and the second oligonucleotide sequence may be different from each other.
6-1	811-816	Again	_	_	
6-2	817-827	regardless	_	_	
6-3	828-830	of	_	_	
6-4	831-838	whether	_	_	
6-5	839-842	the	_	_	
6-6	843-846	two	_	_	
6-7	847-853	probes	_	_	
6-8	854-857	are	_	_	
6-9	858-865	soluble	_	_	
6-10	866-868	or	_	_	
6-11	869-880	immobilized	_	_	
6-12	880-881	,	_	_	
6-13	882-885	the	_	_	
6-14	886-891	first	_	_	
6-15	892-907	oligonucleotide	_	_	
6-16	908-916	sequence	_	_	
6-17	917-920	and	_	_	
6-18	921-924	the	_	_	
6-19	925-931	second	_	_	
6-20	932-947	oligonucleotide	_	_	
6-21	948-956	sequence	_	_	
6-22	957-960	may	_	_	
6-23	961-963	be	_	_	
6-24	964-973	different	_	_	
6-25	974-978	from	_	_	
6-26	979-983	each	_	_	
6-27	984-989	other	_	_	
6-28	989-990	.	_	_	

#Text=In this instance, the first and the second probes can each be self-reporting probes that include a detectable label.
7-1	991-993	In	_	_	
7-2	994-998	this	_	_	
7-3	999-1007	instance	_	_	
7-4	1007-1008	,	_	_	
7-5	1009-1012	the	_	_	
7-6	1013-1018	first	_	_	
7-7	1019-1022	and	_	_	
7-8	1023-1026	the	_	_	
7-9	1027-1033	second	_	_	
7-10	1034-1040	probes	_	_	
7-11	1041-1044	can	_	_	
7-12	1045-1049	each	_	_	
7-13	1050-1052	be	_	_	
7-14	1053-1067	self-reporting	_	_	
7-15	1068-1074	probes	_	_	
7-16	1075-1079	that	_	_	
7-17	1080-1087	include	_	_	
7-18	1088-1089	a	_	_	
7-19	1090-1100	detectable	_	_	
7-20	1101-1106	label	_	_	
7-21	1106-1107	.	_	_	

#Text=In one embodiment, the detectable labels of the two self-reporting probes may be identical detectable labels.
8-1	1108-1110	In	_	_	
8-2	1111-1114	one	_	_	
8-3	1115-1125	embodiment	_	_	
8-4	1125-1126	,	_	_	
8-5	1127-1130	the	_	_	
8-6	1131-1141	detectable	_	_	
8-7	1142-1148	labels	_	_	
8-8	1149-1151	of	_	_	
8-9	1152-1155	the	_	_	
8-10	1156-1159	two	_	_	
8-11	1160-1174	self-reporting	_	_	
8-12	1175-1181	probes	_	_	
8-13	1182-1185	may	_	_	
8-14	1186-1188	be	_	_	
8-15	1189-1198	identical	_	_	
8-16	1199-1209	detectable	_	_	
8-17	1210-1216	labels	_	_	
8-18	1216-1217	.	_	_	

#Text=Again regardless of whether the two probes are soluble or immobilized, the first probe may further include a first detectable label, and the second probe may further include a second detectable label.
9-1	1218-1223	Again	_	_	
9-2	1224-1234	regardless	_	_	
9-3	1235-1237	of	_	_	
9-4	1238-1245	whether	_	_	
9-5	1246-1249	the	_	_	
9-6	1250-1253	two	_	_	
9-7	1254-1260	probes	_	_	
9-8	1261-1264	are	_	_	
9-9	1265-1272	soluble	_	_	
9-10	1273-1275	or	_	_	
9-11	1276-1287	immobilized	_	_	
9-12	1287-1288	,	_	_	
9-13	1289-1292	the	_	_	
9-14	1293-1298	first	_	_	
9-15	1299-1304	probe	_	_	
9-16	1305-1308	may	_	_	
9-17	1309-1316	further	_	_	
9-18	1317-1324	include	_	_	
9-19	1325-1326	a	_	_	
9-20	1327-1332	first	_	_	
9-21	1333-1343	detectable	_	_	
9-22	1344-1349	label	_	_	
9-23	1349-1350	,	_	_	
9-24	1351-1354	and	_	_	
9-25	1355-1358	the	_	_	
9-26	1359-1365	second	_	_	
9-27	1366-1371	probe	_	_	
9-28	1372-1375	may	_	_	
9-29	1376-1383	further	_	_	
9-30	1384-1391	include	_	_	
9-31	1392-1393	a	_	_	
9-32	1394-1400	second	_	_	
9-33	1401-1411	detectable	_	_	
9-34	1412-1417	label	_	_	
9-35	1417-1418	.	_	_	

#Text=When this is the case, the two detectable labels may include either a chemiluminescent moiety or a fluorophore.
10-1	1419-1423	When	_	_	
10-2	1424-1428	this	_	_	
10-3	1429-1431	is	_	_	
10-4	1432-1435	the	_	_	
10-5	1436-1440	case	_	_	
10-6	1440-1441	,	_	_	
10-7	1442-1445	the	_	_	
10-8	1446-1449	two	_	_	
10-9	1450-1460	detectable	_	_	
10-10	1461-1467	labels	_	_	
10-11	1468-1471	may	_	_	
10-12	1472-1479	include	_	_	
10-13	1480-1486	either	_	_	
10-14	1487-1488	a	_	_	
10-15	1489-1505	chemiluminescent	_	_	
10-16	1506-1512	moiety	_	_	
10-17	1513-1515	or	_	_	
10-18	1516-1517	a	_	_	
10-19	1518-1529	fluorophore	_	_	
10-20	1529-1530	.	_	_	

#Text=When the two detectable labels are chemiluminescent moieties, the chemiluminescent moieties may be of identical types.
11-1	1531-1535	When	_	_	
11-2	1536-1539	the	_	_	
11-3	1540-1543	two	_	_	
11-4	1544-1554	detectable	_	_	
11-5	1555-1561	labels	_	_	
11-6	1562-1565	are	_	_	
11-7	1566-1582	chemiluminescent	_	_	
11-8	1583-1591	moieties	_	_	
11-9	1591-1592	,	_	_	
11-10	1593-1596	the	_	_	
11-11	1597-1613	chemiluminescent	_	_	
11-12	1614-1622	moieties	_	_	
11-13	1623-1626	may	_	_	
11-14	1627-1629	be	_	_	
11-15	1630-1632	of	_	_	
11-16	1633-1642	identical	_	_	
11-17	1643-1648	types	_	_	
11-18	1648-1649	.	_	_	

#Text=In a particular case, the identical chemiluminescent moieties include acridinium ester.
12-1	1650-1652	In	_	_	
12-2	1653-1654	a	_	_	
12-3	1655-1665	particular	_	_	
12-4	1666-1670	case	_	_	
12-5	1670-1671	,	_	_	
12-6	1672-1675	the	_	_	
12-7	1676-1685	identical	_	_	
12-8	1686-1702	chemiluminescent	_	_	
12-9	1703-1711	moieties	_	_	
12-10	1712-1719	include	_	_	
12-11	1720-1730	acridinium	_	_	
12-12	1731-1736	ester	_	_	
12-13	1736-1737	.	_	_	

#Text=According to another embodiment, when the first probe and second probes are both soluble probes, they are soluble probes having a linear configuration.
13-1	1738-1747	According	_	_	
13-2	1748-1750	to	_	_	
13-3	1751-1758	another	_	_	
13-4	1759-1769	embodiment	_	_	
13-5	1769-1770	,	_	_	
13-6	1771-1775	when	_	_	
13-7	1776-1779	the	_	_	
13-8	1780-1785	first	_	_	
13-9	1786-1791	probe	_	_	
13-10	1792-1795	and	_	_	
13-11	1796-1802	second	_	_	
13-12	1803-1809	probes	_	_	
13-13	1810-1813	are	_	_	
13-14	1814-1818	both	_	_	
13-15	1819-1826	soluble	_	_	
13-16	1827-1833	probes	_	_	
13-17	1833-1834	,	_	_	
13-18	1835-1839	they	_	_	
13-19	1840-1843	are	_	_	
13-20	1844-1851	soluble	_	_	
13-21	1852-1858	probes	_	_	
13-22	1859-1865	having	_	_	
13-23	1866-1867	a	_	_	
13-24	1868-1874	linear	_	_	
13-25	1875-1888	configuration	_	_	
13-26	1888-1889	.	_	_	

#Text=According to a different embodiment, when both of the probes are immobilized probes, they may be molecular beacon probes.
14-1	1890-1899	According	_	_	
14-2	1900-1902	to	_	_	
14-3	1903-1904	a	_	_	
14-4	1905-1914	different	_	_	
14-5	1915-1925	embodiment	_	_	
14-6	1925-1926	,	_	_	
14-7	1927-1931	when	_	_	
14-8	1932-1936	both	_	_	
14-9	1937-1939	of	_	_	
14-10	1940-1943	the	_	_	
14-11	1944-1950	probes	_	_	
14-12	1951-1954	are	_	_	
14-13	1955-1966	immobilized	_	_	
14-14	1967-1973	probes	_	_	
14-15	1973-1974	,	_	_	
14-16	1975-1979	they	_	_	
14-17	1980-1983	may	_	_	
14-18	1984-1986	be	_	_	
14-19	1987-1996	molecular	_	_	
14-20	1997-2003	beacon	_	_	
14-21	2004-2010	probes	_	_	
14-22	2010-2011	.	_	_	

#Text=According to a different embodiment, and again regardless of whether the two probes are soluble or immobilized, the first probe and the second probe may be first and second self-reporting probes.
15-1	2012-2021	According	_	_	
15-2	2022-2024	to	_	_	
15-3	2025-2026	a	_	_	
15-4	2027-2036	different	_	_	
15-5	2037-2047	embodiment	_	_	
15-6	2047-2048	,	_	_	
15-7	2049-2052	and	_	_	
15-8	2053-2058	again	_	_	
15-9	2059-2069	regardless	_	_	
15-10	2070-2072	of	_	_	
15-11	2073-2080	whether	_	_	
15-12	2081-2084	the	_	_	
15-13	2085-2088	two	_	_	
15-14	2089-2095	probes	_	_	
15-15	2096-2099	are	_	_	
15-16	2100-2107	soluble	_	_	
15-17	2108-2110	or	_	_	
15-18	2111-2122	immobilized	_	_	
15-19	2122-2123	,	_	_	
15-20	2124-2127	the	_	_	
15-21	2128-2133	first	_	_	
15-22	2134-2139	probe	_	_	
15-23	2140-2143	and	_	_	
15-24	2144-2147	the	_	_	
15-25	2148-2154	second	_	_	
15-26	2155-2160	probe	_	_	
15-27	2161-2164	may	_	_	
15-28	2165-2167	be	_	_	
15-29	2168-2173	first	_	_	
15-30	2174-2177	and	_	_	
15-31	2178-2184	second	_	_	
15-32	2185-2199	self-reporting	_	_	
15-33	2200-2206	probes	_	_	
15-34	2206-2207	.	_	_	

#Text=When this is the case, the first and second self-reporting probes may be first and second molecular beacons.
16-1	2208-2212	When	_	_	
16-2	2213-2217	this	_	_	
16-3	2218-2220	is	_	_	
16-4	2221-2224	the	_	_	
16-5	2225-2229	case	_	_	
16-6	2229-2230	,	_	_	
16-7	2231-2234	the	_	_	
16-8	2235-2240	first	_	_	
16-9	2241-2244	and	_	_	
16-10	2245-2251	second	_	_	
16-11	2252-2266	self-reporting	_	_	
16-12	2267-2273	probes	_	_	
16-13	2274-2277	may	_	_	
16-14	2278-2280	be	_	_	
16-15	2281-2286	first	_	_	
16-16	2287-2290	and	_	_	
16-17	2291-2297	second	_	_	
16-18	2298-2307	molecular	_	_	
16-19	2308-2315	beacons	_	_	
16-20	2315-2316	.	_	_	

#Text=In alternative embodiments of this invention, the first and second molecular beacons each include a stem portion and a loop portion, and either the first and second molecular beacons differ from each other in the length of their respective stem portions, or in the length of their respective loop portions.
17-1	2317-2319	In	_	_	
17-2	2320-2331	alternative	_	_	
17-3	2332-2343	embodiments	_	_	
17-4	2344-2346	of	_	_	
17-5	2347-2351	this	_	_	
17-6	2352-2361	invention	_	_	
17-7	2361-2362	,	_	_	
17-8	2363-2366	the	_	_	
17-9	2367-2372	first	_	_	
17-10	2373-2376	and	_	_	
17-11	2377-2383	second	_	_	
17-12	2384-2393	molecular	_	_	
17-13	2394-2401	beacons	_	_	
17-14	2402-2406	each	_	_	
17-15	2407-2414	include	_	_	
17-16	2415-2416	a	_	_	
17-17	2417-2421	stem	_	_	
17-18	2422-2429	portion	_	_	
17-19	2430-2433	and	_	_	
17-20	2434-2435	a	_	_	
17-21	2436-2440	loop	_	_	
17-22	2441-2448	portion	_	_	
17-23	2448-2449	,	_	_	
17-24	2450-2453	and	_	_	
17-25	2454-2460	either	_	_	
17-26	2461-2464	the	_	_	
17-27	2465-2470	first	_	_	
17-28	2471-2474	and	_	_	
17-29	2475-2481	second	_	_	
17-30	2482-2491	molecular	_	_	
17-31	2492-2499	beacons	_	_	
17-32	2500-2506	differ	_	_	
17-33	2507-2511	from	_	_	
17-34	2512-2516	each	_	_	
17-35	2517-2522	other	_	_	
17-36	2523-2525	in	_	_	
17-37	2526-2529	the	_	_	
17-38	2530-2536	length	_	_	
17-39	2537-2539	of	_	_	
17-40	2540-2545	their	_	_	
17-41	2546-2556	respective	_	_	
17-42	2557-2561	stem	_	_	
17-43	2562-2570	portions	_	_	
17-44	2570-2571	,	_	_	
17-45	2572-2574	or	_	_	
17-46	2575-2577	in	_	_	
17-47	2578-2581	the	_	_	
17-48	2582-2588	length	_	_	
17-49	2589-2591	of	_	_	
17-50	2592-2597	their	_	_	
17-51	2598-2608	respective	_	_	
17-52	2609-2613	loop	_	_	
17-53	2614-2622	portions	_	_	
17-54	2622-2623	.	_	_	

#Text=In still another embodiment, at least one of two molecular beacons includes at least one nucleotide analog.
#Text=[0012] Another aspect of the invention relates to a method for quantifying the amount of an analyte polynucleotide contained in a sample over a range extending from a lower limit amount to an upper limit amount.
18-1	2624-2626	In	_	_	
18-2	2627-2632	still	_	_	
18-3	2633-2640	another	_	_	
18-4	2641-2651	embodiment	_	_	
18-5	2651-2652	,	_	_	
18-6	2653-2655	at	_	_	
18-7	2656-2661	least	_	_	
18-8	2662-2665	one	_	_	
18-9	2666-2668	of	_	_	
18-10	2669-2672	two	_	_	
18-11	2673-2682	molecular	_	_	
18-12	2683-2690	beacons	_	_	
18-13	2691-2699	includes	_	_	
18-14	2700-2702	at	_	_	
18-15	2703-2708	least	_	_	
18-16	2709-2712	one	_	_	
18-17	2713-2723	nucleotide	_	_	
18-18	2724-2730	analog	_	_	
18-19	2730-2731	.	_	_	
18-20	2732-2733	[	_	_	
18-21	2733-2737	0012	_	_	
18-22	2737-2738	]	_	_	
18-23	2739-2746	Another	_	_	
18-24	2747-2753	aspect	_	_	
18-25	2754-2756	of	_	_	
18-26	2757-2760	the	_	_	
18-27	2761-2770	invention	_	_	
18-28	2771-2778	relates	_	_	
18-29	2779-2781	to	_	_	
18-30	2782-2783	a	_	_	
18-31	2784-2790	method	_	_	
18-32	2791-2794	for	_	_	
18-33	2795-2806	quantifying	_	_	
18-34	2807-2810	the	_	_	
18-35	2811-2817	amount	_	_	
18-36	2818-2820	of	_	_	
18-37	2821-2823	an	_	_	
18-38	2824-2831	analyte	_	_	
18-39	2832-2846	polynucleotide	_	_	
18-40	2847-2856	contained	_	_	
18-41	2857-2859	in	_	_	
18-42	2860-2861	a	_	_	
18-43	2862-2868	sample	_	_	
18-44	2869-2873	over	_	_	
18-45	2874-2875	a	_	_	
18-46	2876-2881	range	_	_	
18-47	2882-2891	extending	_	_	
18-48	2892-2896	from	_	_	
18-49	2897-2898	a	_	_	
18-50	2899-2904	lower	_	_	
18-51	2905-2910	limit	_	_	
18-52	2911-2917	amount	_	_	
18-53	2918-2920	to	_	_	
18-54	2921-2923	an	_	_	
18-55	2924-2929	upper	_	_	
18-56	2930-2935	limit	_	_	
18-57	2936-2942	amount	_	_	
18-58	2942-2943	.	_	_	

#Text=In accordance with this aspect of the invention, there is first a step for providing a probe reagent in accordance with any of the embodiments of the above-described invention.
19-1	2944-2946	In	_	_	
19-2	2947-2957	accordance	_	_	
19-3	2958-2962	with	_	_	
19-4	2963-2967	this	_	_	
19-5	2968-2974	aspect	_	_	
19-6	2975-2977	of	_	_	
19-7	2978-2981	the	_	_	
19-8	2982-2991	invention	_	_	
19-9	2991-2992	,	_	_	
19-10	2993-2998	there	_	_	
19-11	2999-3001	is	_	_	
19-12	3002-3007	first	_	_	
19-13	3008-3009	a	_	_	
19-14	3010-3014	step	_	_	
19-15	3015-3018	for	_	_	
19-16	3019-3028	providing	_	_	
19-17	3029-3030	a	_	_	
19-18	3031-3036	probe	_	_	
19-19	3037-3044	reagent	_	_	
19-20	3045-3047	in	_	_	
19-21	3048-3058	accordance	_	_	
19-22	3059-3063	with	_	_	
19-23	3064-3067	any	_	_	
19-24	3068-3070	of	_	_	
19-25	3071-3074	the	_	_	
19-26	3075-3086	embodiments	_	_	
19-27	3087-3089	of	_	_	
19-28	3090-3093	the	_	_	
19-29	3094-3109	above-described	_	_	
19-30	3110-3119	invention	_	_	
19-31	3119-3120	.	_	_	

#Text=Next, there is a step for hybridizing the probe reagent and any of the analyte polynucleotide that may be present in the sample.
20-1	3121-3125	Next	_	_	
20-2	3125-3126	,	_	_	
20-3	3127-3132	there	_	_	
20-4	3133-3135	is	_	_	
20-5	3136-3137	a	_	_	
20-6	3138-3142	step	_	_	
20-7	3143-3146	for	_	_	
20-8	3147-3158	hybridizing	_	_	
20-9	3159-3162	the	_	_	
20-10	3163-3168	probe	_	_	
20-11	3169-3176	reagent	_	_	
20-12	3177-3180	and	_	_	
20-13	3181-3184	any	_	_	
20-14	3185-3187	of	_	_	
20-15	3188-3191	the	_	_	
20-16	3192-3199	analyte	_	_	
20-17	3200-3214	polynucleotide	_	_	
20-18	3215-3219	that	_	_	
20-19	3220-3223	may	_	_	
20-20	3224-3226	be	_	_	
20-21	3227-3234	present	_	_	
20-22	3235-3237	in	_	_	
20-23	3238-3241	the	_	_	
20-24	3242-3248	sample	_	_	
20-25	3248-3249	.	_	_	

#Text=This is followed by a step for measuring a signal that indicates the magnitude of hybrid duplex formation in the hybridizing step, and is in turn followed by a step for quantifying from the measured signal the amount of analyte polynucleotide present in the sample.
21-1	3250-3254	This	_	_	
21-2	3255-3257	is	_	_	
21-3	3258-3266	followed	_	_	
21-4	3267-3269	by	_	_	
21-5	3270-3271	a	_	_	
21-6	3272-3276	step	_	_	
21-7	3277-3280	for	_	_	
21-8	3281-3290	measuring	_	_	
21-9	3291-3292	a	_	_	
21-10	3293-3299	signal	_	_	
21-11	3300-3304	that	_	_	
21-12	3305-3314	indicates	_	_	
21-13	3315-3318	the	_	_	
21-14	3319-3328	magnitude	_	_	
21-15	3329-3331	of	_	_	
21-16	3332-3338	hybrid	_	_	
21-17	3339-3345	duplex	_	_	
21-18	3346-3355	formation	_	_	
21-19	3356-3358	in	_	_	
21-20	3359-3362	the	_	_	
21-21	3363-3374	hybridizing	_	_	
21-22	3375-3379	step	_	_	
21-23	3379-3380	,	_	_	
21-24	3381-3384	and	_	_	
21-25	3385-3387	is	_	_	
21-26	3388-3390	in	_	_	
21-27	3391-3395	turn	_	_	
21-28	3396-3404	followed	_	_	
21-29	3405-3407	by	_	_	
21-30	3408-3409	a	_	_	
21-31	3410-3414	step	_	_	
21-32	3415-3418	for	_	_	
21-33	3419-3430	quantifying	_	_	
21-34	3431-3435	from	_	_	
21-35	3436-3439	the	_	_	
21-36	3440-3448	measured	_	_	
21-37	3449-3455	signal	_	_	
21-38	3456-3459	the	_	_	
21-39	3460-3466	amount	_	_	
21-40	3467-3469	of	_	_	
21-41	3470-3477	analyte	_	_	
21-42	3478-3492	polynucleotide	_	_	
21-43	3493-3500	present	_	_	
21-44	3501-3503	in	_	_	
21-45	3504-3507	the	_	_	
21-46	3508-3514	sample	_	_	
21-47	3514-3515	.	_	_	

#Text=In accordance with different embodiments of the invention, either the first and second probes of the invented reagent are both soluble probes, or the first and second probes of the invented reagent are both immobilized probes.
22-1	3516-3518	In	_	_	
22-2	3519-3529	accordance	_	_	
22-3	3530-3534	with	_	_	
22-4	3535-3544	different	_	_	
22-5	3545-3556	embodiments	_	_	
22-6	3557-3559	of	_	_	
22-7	3560-3563	the	_	_	
22-8	3564-3573	invention	_	_	
22-9	3573-3574	,	_	_	
22-10	3575-3581	either	_	_	
22-11	3582-3585	the	_	_	
22-12	3586-3591	first	_	_	
22-13	3592-3595	and	_	_	
22-14	3596-3602	second	_	_	
22-15	3603-3609	probes	_	_	
22-16	3610-3612	of	_	_	
22-17	3613-3616	the	_	_	
22-18	3617-3625	invented	_	_	
22-19	3626-3633	reagent	_	_	
22-20	3634-3637	are	_	_	
22-21	3638-3642	both	_	_	
22-22	3643-3650	soluble	_	_	
22-23	3651-3657	probes	_	_	
22-24	3657-3658	,	_	_	
22-25	3659-3661	or	_	_	
22-26	3662-3665	the	_	_	
22-27	3666-3671	first	_	_	
22-28	3672-3675	and	_	_	
22-29	3676-3682	second	_	_	
22-30	3683-3689	probes	_	_	
22-31	3690-3692	of	_	_	
22-32	3693-3696	the	_	_	
22-33	3697-3705	invented	_	_	
22-34	3706-3713	reagent	_	_	
22-35	3714-3717	are	_	_	
22-36	3718-3722	both	_	_	
22-37	3723-3734	immobilized	_	_	
22-38	3735-3741	probes	_	_	
22-39	3741-3742	.	_	_	

#Text=In another embodiment, the quantifying step involves comparing the measured hybridization signal to a standard curve.
23-1	3743-3745	In	_	_	
23-2	3746-3753	another	_	_	
23-3	3754-3764	embodiment	_	_	
23-4	3764-3765	,	_	_	
23-5	3766-3769	the	_	_	
23-6	3770-3781	quantifying	_	_	
23-7	3782-3786	step	_	_	
23-8	3787-3795	involves	_	_	
23-9	3796-3805	comparing	_	_	
23-10	3806-3809	the	_	_	
23-11	3810-3818	measured	_	_	
23-12	3819-3832	hybridization	_	_	
23-13	3833-3839	signal	_	_	
23-14	3840-3842	to	_	_	
23-15	3843-3844	a	_	_	
23-16	3845-3853	standard	_	_	
23-17	3854-3859	curve	_	_	
23-18	3859-3860	.	_	_	

#Text=In yet another embodiment of the invention, the measuring step involves making an optical measurement.
24-1	3861-3863	In	_	_	
24-2	3864-3867	yet	_	_	
24-3	3868-3875	another	_	_	
24-4	3876-3886	embodiment	_	_	
24-5	3887-3889	of	_	_	
24-6	3890-3893	the	_	_	
24-7	3894-3903	invention	_	_	
24-8	3903-3904	,	_	_	
24-9	3905-3908	the	_	_	
24-10	3909-3918	measuring	_	_	
24-11	3919-3923	step	_	_	
24-12	3924-3932	involves	_	_	
24-13	3933-3939	making	_	_	
24-14	3940-3942	an	_	_	
24-15	3943-3950	optical	_	_	
24-16	3951-3962	measurement	_	_	
24-17	3962-3963	.	_	_	

#Text=When this is the case, the measuring step may alternatively involve performing luminometry, or measuring by fluorometry.
#Text=[0013] Yet another aspect of the invention relates to a method of making a probe reagent for quantifying an analyte polynucleotide.
25-1	3964-3968	When	_	_	
25-2	3969-3973	this	_	_	
25-3	3974-3976	is	_	_	
25-4	3977-3980	the	_	_	
25-5	3981-3985	case	_	_	
25-6	3985-3986	,	_	_	
25-7	3987-3990	the	_	_	
25-8	3991-4000	measuring	_	_	
25-9	4001-4005	step	_	_	
25-10	4006-4009	may	_	_	
25-11	4010-4023	alternatively	_	_	
25-12	4024-4031	involve	_	_	
25-13	4032-4042	performing	_	_	
25-14	4043-4054	luminometry	_	_	
25-15	4054-4055	,	_	_	
25-16	4056-4058	or	_	_	
25-17	4059-4068	measuring	_	_	
25-18	4069-4071	by	_	_	
25-19	4072-4083	fluorometry	_	_	
25-20	4083-4084	.	_	_	
25-21	4085-4086	[	_	_	
25-22	4086-4090	0013	_	_	
25-23	4090-4091	]	_	_	
25-24	4092-4095	Yet	_	_	
25-25	4096-4103	another	_	_	
25-26	4104-4110	aspect	_	_	
25-27	4111-4113	of	_	_	
25-28	4114-4117	the	_	_	
25-29	4118-4127	invention	_	_	
25-30	4128-4135	relates	_	_	
25-31	4136-4138	to	_	_	
25-32	4139-4140	a	*[1]	26-3[2_1]	
25-33	4141-4147	method	*[1]	_	
25-34	4148-4150	of	*[1]	_	
25-35	4151-4157	making	*[1]	_	
25-36	4158-4159	a	*[1]	_	
25-37	4160-4165	probe	*[1]	_	
25-38	4166-4173	reagent	*[1]	_	
25-39	4174-4177	for	*[1]	_	
25-40	4178-4189	quantifying	*[1]	_	
25-41	4190-4192	an	*[1]	_	
25-42	4193-4200	analyte	*[1]	_	
25-43	4201-4215	polynucleotide	*[1]	_	
25-44	4215-4216	.	_	_	

#Text=According to this method, there is a step for selecting a first oligonucleotide probe that is complementary to a first analyte sequence which is contained within the analyte polynucleotide.
26-1	4217-4226	According	_	_	
26-2	4227-4229	to	_	_	
26-3	4230-4234	this	*[2]	_	
26-4	4235-4241	method	*[2]	_	
26-5	4241-4242	,	_	_	
26-6	4243-4248	there	_	_	
26-7	4249-4251	is	_	_	
26-8	4252-4253	a	_	_	
26-9	4254-4258	step	_	_	
26-10	4259-4262	for	_	_	
26-11	4263-4272	selecting	_	_	
26-12	4273-4274	a	_	_	
26-13	4275-4280	first	_	_	
26-14	4281-4296	oligonucleotide	_	_	
26-15	4297-4302	probe	_	_	
26-16	4303-4307	that	_	_	
26-17	4308-4310	is	_	_	
26-18	4311-4324	complementary	_	_	
26-19	4325-4327	to	_	_	
26-20	4328-4329	a	_	_	
26-21	4330-4335	first	_	_	
26-22	4336-4343	analyte	_	_	
26-23	4344-4352	sequence	_	_	
26-24	4353-4358	which	_	_	
26-25	4359-4361	is	_	_	
26-26	4362-4371	contained	_	_	
26-27	4372-4378	within	_	_	
26-28	4379-4382	the	_	_	
26-29	4383-4390	analyte	_	_	
26-30	4391-4405	polynucleotide	_	_	
26-31	4405-4406	.	_	_	

#Text=This first oligonucleotide probe is capable of hybridizing to the analyte polynucleotide to form a first duplex having a first affinity.
27-1	4407-4411	This	_	_	
27-2	4412-4417	first	_	_	
27-3	4418-4433	oligonucleotide	_	_	
27-4	4434-4439	probe	_	_	
27-5	4440-4442	is	_	_	
27-6	4443-4450	capable	_	_	
27-7	4451-4453	of	_	_	
27-8	4454-4465	hybridizing	_	_	
27-9	4466-4468	to	_	_	
27-10	4469-4472	the	_	_	
27-11	4473-4480	analyte	_	_	
27-12	4481-4495	polynucleotide	_	_	
27-13	4496-4498	to	_	_	
27-14	4499-4503	form	_	_	
27-15	4504-4505	a	_	_	
27-16	4506-4511	first	_	_	
27-17	4512-4518	duplex	_	_	
27-18	4519-4525	having	_	_	
27-19	4526-4527	a	_	_	
27-20	4528-4533	first	_	_	
27-21	4534-4542	affinity	_	_	
27-22	4542-4543	.	_	_	

#Text=This is followed by a step for selecting a second oligonucleotide probe that is complementary to a second analyte sequence which also is contained within the analyte polynucleotide.
28-1	4544-4548	This	_	_	
28-2	4549-4551	is	_	_	
28-3	4552-4560	followed	_	_	
28-4	4561-4563	by	_	_	
28-5	4564-4565	a	_	_	
28-6	4566-4570	step	_	_	
28-7	4571-4574	for	_	_	
28-8	4575-4584	selecting	_	_	
28-9	4585-4586	a	_	_	
28-10	4587-4593	second	_	_	
28-11	4594-4609	oligonucleotide	_	_	
28-12	4610-4615	probe	_	_	
28-13	4616-4620	that	_	_	
28-14	4621-4623	is	_	_	
28-15	4624-4637	complementary	_	_	
28-16	4638-4640	to	_	_	
28-17	4641-4642	a	_	_	
28-18	4643-4649	second	_	_	
28-19	4650-4657	analyte	_	_	
28-20	4658-4666	sequence	_	_	
28-21	4667-4672	which	_	_	
28-22	4673-4677	also	_	_	
28-23	4678-4680	is	_	_	
28-24	4681-4690	contained	_	_	
28-25	4691-4697	within	_	_	
28-26	4698-4701	the	_	_	
28-27	4702-4709	analyte	_	_	
28-28	4710-4724	polynucleotide	_	_	
28-29	4724-4725	.	_	_	

#Text=This second oligonucleotide probe is capable of hybridizing to the analyte polynucleotide to form a second duplex having a second affinity.
29-1	4726-4730	This	_	_	
29-2	4731-4737	second	_	_	
29-3	4738-4753	oligonucleotide	_	_	
29-4	4754-4759	probe	_	_	
29-5	4760-4762	is	_	_	
29-6	4763-4770	capable	_	_	
29-7	4771-4773	of	_	_	
29-8	4774-4785	hybridizing	_	_	
29-9	4786-4788	to	_	_	
29-10	4789-4792	the	_	_	
29-11	4793-4800	analyte	_	_	
29-12	4801-4815	polynucleotide	_	_	
29-13	4816-4818	to	_	_	
29-14	4819-4823	form	_	_	
29-15	4824-4825	a	_	_	
29-16	4826-4832	second	_	_	
29-17	4833-4839	duplex	_	_	
29-18	4840-4846	having	_	_	
29-19	4847-4848	a	_	_	
29-20	4849-4855	second	_	_	
29-21	4856-4864	affinity	_	_	
29-22	4864-4865	.	_	_	

#Text=The first affinity and the second affinity are different from each other.
30-1	4866-4869	The	_	_	
30-2	4870-4875	first	_	_	
30-3	4876-4884	affinity	_	_	
30-4	4885-4888	and	_	_	
30-5	4889-4892	the	_	_	
30-6	4893-4899	second	_	_	
30-7	4900-4908	affinity	_	_	
30-8	4909-4912	are	_	_	
30-9	4913-4922	different	_	_	
30-10	4923-4927	from	_	_	
30-11	4928-4932	each	_	_	
30-12	4933-4938	other	_	_	
30-13	4938-4939	.	_	_	

#Text=One test for ensuring that different oligonucleotide probes hybridize to their respective analyte sequences with different affinities is to ensure that the two probe:target hybrids have different Tms when measured under identical buffer conditions and probe and target concentrations.
31-1	4940-4943	One	_	_	
31-2	4944-4948	test	_	_	
31-3	4949-4952	for	_	_	
31-4	4953-4961	ensuring	_	_	
31-5	4962-4966	that	_	_	
31-6	4967-4976	different	_	_	
31-7	4977-4992	oligonucleotide	_	_	
31-8	4993-4999	probes	_	_	
31-9	5000-5009	hybridize	_	_	
31-10	5010-5012	to	_	_	
31-11	5013-5018	their	_	_	
31-12	5019-5029	respective	_	_	
31-13	5030-5037	analyte	_	_	
31-14	5038-5047	sequences	_	_	
31-15	5048-5052	with	_	_	
31-16	5053-5062	different	_	_	
31-17	5063-5073	affinities	_	_	
31-18	5074-5076	is	_	_	
31-19	5077-5079	to	_	_	
31-20	5080-5086	ensure	_	_	
31-21	5087-5091	that	_	_	
31-22	5092-5095	the	_	_	
31-23	5096-5099	two	_	_	
31-24	5100-5105	probe	_	_	
31-25	5105-5106	:	_	_	
31-26	5106-5112	target	_	_	
31-27	5113-5120	hybrids	_	_	
31-28	5121-5125	have	_	_	
31-29	5126-5135	different	_	_	
31-30	5136-5139	Tms	_	_	
31-31	5140-5144	when	_	_	
31-32	5145-5153	measured	_	_	
31-33	5154-5159	under	_	_	
31-34	5160-5169	identical	_	_	
31-35	5170-5176	buffer	_	_	
31-36	5177-5187	conditions	_	_	
31-37	5188-5191	and	_	_	
31-38	5192-5197	probe	_	_	
31-39	5198-5201	and	_	_	
31-40	5202-5208	target	_	_	
31-41	5209-5223	concentrations	_	_	
31-42	5223-5224	.	_	_	

#Text=In accordance with the invention, the first analyte sequence and the second analyte sequence are contiguous with each other and share at least one nucleotide position in common.
32-1	5225-5227	In	_	_	
32-2	5228-5238	accordance	_	_	
32-3	5239-5243	with	_	_	
32-4	5244-5247	the	_	_	
32-5	5248-5257	invention	_	_	
32-6	5257-5258	,	_	_	
32-7	5259-5262	the	_	_	
32-8	5263-5268	first	_	_	
32-9	5269-5276	analyte	_	_	
32-10	5277-5285	sequence	_	_	
32-11	5286-5289	and	_	_	
32-12	5290-5293	the	_	_	
32-13	5294-5300	second	_	_	
32-14	5301-5308	analyte	_	_	
32-15	5309-5317	sequence	_	_	
32-16	5318-5321	are	_	_	
32-17	5322-5332	contiguous	_	_	
32-18	5333-5337	with	_	_	
32-19	5338-5342	each	_	_	
32-20	5343-5348	other	_	_	
32-21	5349-5352	and	_	_	
32-22	5353-5358	share	_	_	
32-23	5359-5361	at	_	_	
32-24	5362-5367	least	_	_	
32-25	5368-5371	one	_	_	
32-26	5372-5382	nucleotide	_	_	
32-27	5383-5391	position	_	_	
32-28	5392-5394	in	_	_	
32-29	5395-5401	common	_	_	
32-30	5401-5402	.	_	_	

#Text=After the probes are selected, they are next combined.
33-1	5403-5408	After	_	_	
33-2	5409-5412	the	_	_	
33-3	5413-5419	probes	_	_	
33-4	5420-5423	are	_	_	
33-5	5424-5432	selected	_	_	
33-6	5432-5433	,	_	_	
33-7	5434-5438	they	_	_	
33-8	5439-5442	are	_	_	
33-9	5443-5447	next	_	_	
33-10	5448-5456	combined	_	_	
33-11	5456-5457	.	_	_	

#Text=In one embodiment, the first oligonucleotide probe comprises a first detectable label and the second oligonucleotide probe comprises a second label.
34-1	5458-5460	In	_	_	
34-2	5461-5464	one	_	_	
34-3	5465-5475	embodiment	_	_	
34-4	5475-5476	,	_	_	
34-5	5477-5480	the	_	_	
34-6	5481-5486	first	_	_	
34-7	5487-5502	oligonucleotide	_	_	
34-8	5503-5508	probe	_	_	
34-9	5509-5518	comprises	_	_	
34-10	5519-5520	a	_	_	
34-11	5521-5526	first	_	_	
34-12	5527-5537	detectable	_	_	
34-13	5538-5543	label	_	_	
34-14	5544-5547	and	_	_	
34-15	5548-5551	the	_	_	
34-16	5552-5558	second	_	_	
34-17	5559-5574	oligonucleotide	_	_	
34-18	5575-5580	probe	_	_	
34-19	5581-5590	comprises	_	_	
34-20	5591-5592	a	_	_	
34-21	5593-5599	second	_	_	
34-22	5600-5605	label	_	_	
34-23	5605-5606	.	_	_	

#Text=In certain embodiments, the first and second detectable labels are identical.
35-1	5607-5609	In	_	_	
35-2	5610-5617	certain	_	_	
35-3	5618-5629	embodiments	_	_	
35-4	5629-5630	,	_	_	
35-5	5631-5634	the	_	_	
35-6	5635-5640	first	_	_	
35-7	5641-5644	and	_	_	
35-8	5645-5651	second	_	_	
35-9	5652-5662	detectable	_	_	
35-10	5663-5669	labels	_	_	
35-11	5670-5673	are	_	_	
35-12	5674-5683	identical	_	_	
35-13	5683-5684	.	_	_	

#Text=In a different embodiment of the invented method, there is an additional step for immobilizing the combined probes to a solid support.
36-1	5685-5687	In	_	_	
36-2	5688-5689	a	_	_	
36-3	5690-5699	different	_	_	
36-4	5700-5710	embodiment	_	_	
36-5	5711-5713	of	_	_	
36-6	5714-5717	the	_	_	
36-7	5718-5726	invented	_	_	
36-8	5727-5733	method	_	_	
36-9	5733-5734	,	_	_	
36-10	5735-5740	there	_	_	
36-11	5741-5743	is	_	_	
36-12	5744-5746	an	_	_	
36-13	5747-5757	additional	_	_	
36-14	5758-5762	step	_	_	
36-15	5763-5766	for	_	_	
36-16	5767-5779	immobilizing	_	_	
36-17	5780-5783	the	_	_	
36-18	5784-5792	combined	_	_	
36-19	5793-5799	probes	_	_	
36-20	5800-5802	to	_	_	
36-21	5803-5804	a	_	_	
36-22	5805-5810	solid	_	_	
36-23	5811-5818	support	_	_	
36-24	5818-5819	.	_	_	

#Text=DEFINITIONS
#Text=[0014] The following terms have the following meanings for the purposes of this disclosure, unless expressly stated to the contrary herein.
37-1	5820-5831	DEFINITIONS	_	_	
37-2	5832-5833	[	_	_	
37-3	5833-5837	0014	_	_	
37-4	5837-5838	]	_	_	
37-5	5839-5842	The	_	_	
37-6	5843-5852	following	_	_	
37-7	5853-5858	terms	_	_	
37-8	5859-5863	have	_	_	
37-9	5864-5867	the	_	_	
37-10	5868-5877	following	_	_	
37-11	5878-5886	meanings	_	_	
37-12	5887-5890	for	_	_	
37-13	5891-5894	the	_	_	
37-14	5895-5903	purposes	_	_	
37-15	5904-5906	of	_	_	
37-16	5907-5911	this	_	_	
37-17	5912-5922	disclosure	_	_	
37-18	5922-5923	,	_	_	
37-19	5924-5930	unless	_	_	
37-20	5931-5940	expressly	_	_	
37-21	5941-5947	stated	_	_	
37-22	5948-5950	to	_	_	
37-23	5951-5954	the	_	_	
37-24	5955-5963	contrary	_	_	
37-25	5964-5970	herein	_	_	
37-26	5970-5971	.	_	_	
